Open AccessOpyt primeneniya preparata Orsoten (orlistat)u bol'nykh ozhireniem
Author(s) -
Galina Melnichenko,
K. A. Komshilova,
M A Berkovskaya
Publication year - 2010
Publication title -
ožirenie i metabolizm
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.154
H-Index - 5
eISSN - 2306-5524
pISSN - 2071-8713
DOI - 10.14341/2071-8713-5278
Subject(s) - orlistat , overweight , medicine , anti obesity , obesity , pharmacotherapy , drug , pharmacology , weight loss
At present, the epidemic of overweight and obesity is one of the most pressing public health problems worldwide.Pharmacotherapy is often initiated to increase the effectiveness of obesity therapy, including orlistat, which is a long-acting inhibitor ofgastric and pancreatic lipases that reduces splitting and subsequent absorption of fat food. Till the recent time the only available orlistatpreparation was Xenical (F. Hoffman La Roche Ltd, Switzerland). In 2009, in Russia was registered another trade name of drug - Orsoten(KRKA, Slovenia), which is the first generic drug orlistat. The article shows the results of a study conducted to examine the clinicalequivalence, efficacy and safety of the drug Orsoten compared with Xenical in obese patients.